🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease

RecruitingPhase 4Ages 18 Years - 80 YearsAllThe University of Texas Medical Branch, Galveston
NCT07203287 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The purpose of the study is to determine which combination of neuromuscular blocking agent and reversal agent is safer to use during anesthesia for patients with chronic kidney disease. The main question it aims to answer is "The use of Cisatracurium with neostigmine leads to less post-operative pulmonary complications than Rocuronium with sugammadex."

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * The subject is able and willing to provide and sign informed consent * The subject must be between 18 and 80 years of age * The subject should have chronic kidney disease as defined by glomerular filtration rate * The surgery must require general anesthesia with endotracheal intubation and neuromuscular blockade Exclusion Criteria: * Any patient under the age of 18 * Any patient over the age of 80 * Any patient with end stage renal disease * Any patient requiring dialysis * Patients presenting for Renal Transplantation * Pregnant Female * Any patient in the correctional system * Urgent or Emergent procedure * The surgery requires intubation post-operatively * Documented allergy to Rocuronium, Sugammadex, Cisatracurium or Neostigmine
💊

What it tests

  • Rocuronium
  • Cisatracurium
  • Sugammadex
  • Neostigmine
📍

Where

1 site
University of Texas Medical Branch
Galveston, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy